MRK Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, MRK is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
MRK has ATR of 2-4% and is a defensive large-cap pharma with above-market dividend yield. Post-earnings moves of 4-8% are typical.
Merck is one of the world's largest pharmaceutical companies, with Keytruda (pembrolizumab). The world's best-selling oncology drug. As its dominant asset. Keytruda generated $25B+ in 2024 revenue across 40+ cancer indications and is the foundation of Merck's oncology franchise. Merck's Animal Health division is the world's second-largest animal health business. A key challenge is the Keytruda patent cliff approaching 2028-2032, which Merck is addressing through pipeline expansion (subcutaneous Keytruda formulation, next-gen oncology, WINREVAIR for pulmonary arterial hypertension).
Why Do Traders Watch MRK?
MRK has ATR of 2-4% and is a defensive large-cap pharma with above-market dividend yield. Post-earnings moves of 4-8% are typical. The Keytruda patent cliff is the central long-term question. Merck must develop $15-20B in new revenue by 2030 to offset Keytruda biosimilar competition. Each new Keytruda indication approval and each promising pipeline asset in Phase 3 is a major catalyst. IRA drug pricing negotiation for Keytruda (effective 2028) is a significant ongoing regulatory risk.
Is MRK a Buy Right Now? Current Signal Readings
Keytruda's revenue growth rate. Still growing 15-20% annually despite being a $25B drug. Demonstrates that new cancer indications, geographic market expansion, and combination therapy usage are extending the growth curve well above analyst models. Each new Keytruda FDA approval adds $500M-2B to the revenue ceiling. Track the FDA approval calendar for pending Keytruda sNDA submissions quarterly.
Merck's post-Keytruda revenue pipeline. WINREVAIR (pulmonary hypertension, $3B+ peak sales potential), islatravir (HIV with Gilead), MK-7684A (TIGIT combination oncology), and the subcutaneous Keytruda formulation. Is the valuation debate. Phase 3 data readouts for any asset showing 40%+ improvement in primary endpoints against standard of care is a 5-10% MRK catalyst.
MRK's RSI operates in a defensive band with spikes during FDA binary events (approval/rejection). RSI dips to 36-40 during broader pharma sector pressure or generic drug pricing legislation concerns. While Keytruda growth is intact. Have been reliable entry points providing dividend income cushion while awaiting catalyst recovery.
The Inflation Reduction Act's Medicare drug price negotiation directly affects Keytruda starting in 2028. The negotiated price reduction (likely 50-65% discount to list price) will reduce Merck's Medicare Keytruda revenue by $3-5B annually from 2028. Track CMS negotiation timeline announcements and Merck's mitigation strategy (SC Keytruda avoiding small molecule negotiation criteria) as key risk-management indicators.
📋 MRK Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze MRK Free →